Meeting
2021 ASCO Annual Meeting
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
Presenter
Martin F. Kaiser, MD
The Institute for Cancer Research
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03188172
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8001)
DOI
10.1200/JCO.2021.39.15_suppl.8001
Abstract #
8001
Abstract Disclosures
Similar Videos & Slides
Speaker: Michael Andrew Postow, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Speaker: Patrick Hagen, MD, MPH
Videos & Slides
2022 ASCO Annual Meeting
Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
Speaker: Cesar Rodriguez, MD
Videos & Slides
2021 ASCO Annual Meeting
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.
Speaker: Robert M. Rifkin, MD, FACP